Proya Cosmetics unveils AI-powered beauty innovation strategy at Cosmetic 360 in Paris

Proya Cosmetics Co., Ltd. (SSE: 603605), one of China’s fastest-growing beauty and personal care players, revealed an ambitious technology-first vision at the 11th edition of Cosmetic 360, held at the Carrousel du Louvre in Paris. The Shanghai-listed company is positioning itself as a global innovator in AI-powered cosmetics by demonstrating how artificial intelligence is now embedded across its research and development, consumer analytics, manufacturing workflows, and precision marketing strategy.

The 2025 theme for Cosmetic 360 — “Predictions” — aligned closely with Proya Cosmetics’ long-term global expansion thesis. The company’s founder and chairman, Hou Juncheng, emphasized that innovation and anticipation are central to its next phase, reinforcing the brand’s shift from a domestic success story into an international beauty contender. The Hangzhou-headquartered cosmetics firm’s presentation at the event included product spotlights, AI integration strategies, and clinical claims aimed at reshaping global perception of Chinese beauty brands.

Founded in 2003 and publicly listed since 2017, Proya Cosmetics has rapidly emerged as a leader in China’s R&D-led premium beauty segment. With a multi-brand portfolio and extensive investment in proprietary formulation and clinical validation, the firm is now focused on elevating its profile among global buyers, industry analysts, and institutional investors seeking growth beyond saturated Western markets.

What AI-driven innovations did Proya Cosmetics highlight in its Cosmetic 360 showcase?

At the event, Proya Cosmetics demonstrated how artificial intelligence is no longer a standalone research tool but a horizontal enabler across its product life cycle. AI applications featured prominently in consumer sentiment mapping, early-stage molecular testing, ingredient prediction, synergistic formulation development, and smart manufacturing. The firm also spotlighted AI’s role in adapting products to changing user behavior and physiological needs across different skin types and geographies.

One of the core R&D highlights was the PROYA Advanced Firming Nourishing Essence 3.0, marketed under the flagship PROYA brand. The product features Cyclopeptide-161, which is the first cyclic peptide to be formally registered with China’s National Medical Products Administration (NMPA). According to clinical validation conducted by SGS, the product delivers a measurable reduction in eight types of wrinkles, including a 58.59% decrease in frown lines after four weeks. The formula was also found to reduce irritation potential by 72% in repeat patch testing, with all study participants reporting a high level of skin tolerance.

In the color cosmetics category, the firm showcased the TIMAGE Cloud Radiant Cushion Foundation and Concealer. The dual-layer design combines an ultra-fine cushion powder for lightweight glow and a bottom-layer concealer for targeted correction. This product features patented Magnetic Skin-Adhering Powder for flawless adhesion and encapsulated hyaluronic acid particles that hydrate dry areas while absorbing excess sebum.

Off&Relax, the group’s dermatological haircare brand, focused on scalp health innovation. It presented its Anti-Dandruff Series that leverages Magnetic Dandruff-Cleaning Technology using a positively charged polymer to neutralize the negatively charged Malassezia fungus without disrupting scalp pH. A complementary AM-124 Microecological Regulation Technology rebalances microbial populations, selectively inhibiting harmful bacteria and promoting beneficial ones. Clinical validation from Shanghai Skin Disease Hospital reported a significant reduction in visible dandruff with no recurrence two weeks after use.

How does Proya’s R&D strategy reflect broader global beauty market shifts in 2025?

Proya Cosmetics’ emphasis on clinically tested, high-performance products with biotech or dermatological claims mirrors the global premiumization trend in skincare. With Chinese consumer sentiment stabilizing and the domestic beauty market entering a maturity phase, top-tier firms like Proya are pursuing international exposure, value-added formulations, and data-driven personalization to retain their competitive edge.

By deploying AI across formulation development, efficacy testing, and marketing optimization, Proya Cosmetics is aligning with the playbooks of multinational conglomerates such as L’Oréal and Estée Lauder. However, it is also using its access to local ingredient databases and Chinese dermatological data to develop products specifically tuned to East Asian and emerging market consumers — a differentiator when exporting to Southeast Asia, the Middle East, and Europe.

Moreover, the company’s collaboration with a synthetic biology firm for AI-based molecular prediction suggests an advanced stage of digital R&D integration. Its proprietary SaaS-enabled AI platform enables Proya to accelerate ingredient testing and significantly improve success rates in preclinical stages — a capability that could dramatically reduce time-to-market for new formulations.

Dr. Sun Peiwen, Director of R&D and Innovation at Proya Cosmetics, presented the AI-based predictive formulation work at the Paris event, highlighting how novel ingredient synergies are discovered via AI models trained on multi-omic data layers, clinical feedback, and ingredient interaction simulations.

What is the investor sentiment and stock performance outlook for Proya Cosmetics in 2025?

As of October 2025, Proya Cosmetics (SSE: 603605) remains one of the most closely watched publicly traded Chinese beauty stocks. With annual revenue having crossed RMB 10 billion (approximately USD 1.4 billion) in FY24, the company has stated a long-term ambition to become one of the world’s top 10 beauty groups.

Institutional investor sentiment has remained largely positive, with particular interest in the company’s ability to leverage its nine-brand architecture for cross-category expansion. Analysts tracking Proya point to its well-balanced margin structure, steady gross profit growth, and expanding R&D allocation as positive indicators of long-term resilience. However, investor focus is now shifting toward international revenue generation and evidence of cross-border consumer traction.

While Proya’s domestic dominance is no longer in question, the extent to which its brand equity translates internationally remains a key stock catalyst. Trading volumes on the Shanghai Stock Exchange have shown elevated activity since Q2 2025, with foreign institutional flows beginning to pick up as international beauty buyers take greater interest in Asian R&D-led brands.

Analysts are also watching for key signals such as: (1) revenue contribution from international markets over the next three quarters, (2) new patents filed through WIPO, (3) strategic partnerships with global ingredient labs, and (4) overseas distribution channel growth, especially in EU markets post-Cosmetic 360.

What execution risks could impact Proya’s global expansion and innovation strategy?

Despite its strong showing in Paris and a compelling innovation narrative, Proya Cosmetics faces significant execution risk on several fronts. Globalization of product lines that were originally formulated for Chinese regulatory standards and skin biology may require reformulation and retesting. Regulatory approvals outside Asia may take longer than anticipated, especially for products featuring novel peptides or biotech-derived ingredients.

Brand perception is another challenge. While Proya is widely trusted in China, penetrating the highly competitive and brand-conscious Western markets requires sustained investment in storytelling, retail partnerships, and authenticity-driven marketing. Furthermore, expansion via potential M&A in Europe or North America, as has been speculated in some trade circles, may stretch management bandwidth and pose integration risks.

At the product level, continued clinical validation and safety testing will be essential to maintain credibility in premium segments. AI-led ingredient innovation is a differentiator, but claims must continue to be backed by third-party trials, dermatological certifications, and post-market safety data to sustain consumer and regulator confidence.

How could Proya Cosmetics’ next 12–18 months shape its transformation from a Chinese beauty leader into a global innovation powerhouse?

Looking ahead, stakeholders can expect Proya Cosmetics to double down on its innovation investments while simultaneously building brand equity beyond China. The most critical near-term milestones will likely include expanded retail partnerships in EU and Southeast Asia, licensing of patented skincare technologies to global collaborators, and the rollout of new product lines co-developed via AI-powered molecular platforms.

Proya’s continued presence in international events such as Cosmetic 360 signals a longer-term positioning move — not just to participate in the global cosmetics conversation, but to shape it. If its AI-first beauty model, validated through strong clinical and market metrics, gains traction abroad, the company could redefine how Chinese R&D firms are viewed in the global beauty ecosystem.

For investors, analysts, and industry observers, the question is no longer whether Proya can innovate — but whether it can scale that innovation globally without diluting its science-driven DNA.

What are the key takeaways from Proya Cosmetics’ innovation showcase and global strategy update?

• Proya Cosmetics used its presence at Cosmetic 360 in Paris to unveil a bold AI-led innovation strategy, applying artificial intelligence across R&D, manufacturing, and marketing.
• The flagship PROYA brand introduced a clinically validated anti-aging essence featuring Cyclopeptide-161, a patented cyclic peptide registered with China’s NMPA.
• Color cosmetics brand TIMAGE and scalp care line Off&Relax showcased advanced technologies, including encapsulated hyaluronic acid powders and microecological scalp regulation.
• The Chinese beauty firm is actively investing in partnerships with AI and synthetic biology companies to accelerate molecular-level ingredient discovery and product testing.
• Institutional sentiment remains optimistic, with analysts focused on Proya’s ability to translate domestic brand equity into global traction, especially in premium skincare segments.
• Key metrics to watch over the next 12–18 months include international revenue contribution, overseas retail expansion, new patent filings, and clinical data from AI-developed products.
• Execution risk remains high due to regulatory complexities, brand localization challenges, and the competitive nature of the global cosmetics market.